诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品

美股速递03-09 20:31

诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。

Hims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。

作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1174808259?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-09 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174808259","market":"us","top_or_hot":-1,"title":"诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品","media":"美股速递","content":"<p>诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。</p>\n<p>Hims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。</p>\n<p>作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-09 20:31 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。\nHims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。\n作为全球GLP...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMZ","symbol_name":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","start_time":0,"source_url":"","article_id":"1174808259","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174808259","pubTimestamp":1773059466,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。\nHims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。\n作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","NVO":"诺和诺德","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF"},"translate_title":"Novo Nordisk: Hims & Hers will stop promoting compound GLP-1 products in platform and marketing","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"HIMY":1,"HIYY":1,"HIMZ":1,"HMYY":1,"HIMS":1},"content_text":"诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。\nHims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。\n作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174808259","isCrawlerRequest":true}